Johnson & JohnsonvsZymeworks

JNJ and ZYME stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $681B and Zymeworks (ZYME) $1.8B. Over the last year, with dividends, JNJ moved +47.5% and ZYME +42.8%. The P/E is 42.3 for JNJ and 42.2 for ZYME. Dividend yield: JNJ 1.87%, ZYME none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$681B

    ZYME$1.8B

    JNJ is 373 times ZYME

  • Revenue, 12 months

    JNJ$99.3B

    ZYME$266M

    JNJ is 373 times ZYME

  • Net income, 12 months

    JNJ$16.1B

    ZYME$43M

    JNJ is 372 times ZYME

  • Operating margin

    JNJ–

    ZYME16.6%

  • ROIC

    JNJ12.4%

    ZYME16.0%

    3.6 points apart

  • P/E

    JNJ42.3

    ZYME42.2

    About the same

  • Dividend yield

    JNJ1.9%

    ZYME0.0%

    1.9 points apart

  • 5-year return

    JNJ+98.6%

    ZYME+35.4%

    63.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+98.6%

ZYME+35.4%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsZYMEWith dividends
1 year since November 14, 2025+47.5%Price +44.2%+42.8%Price +42.8%
3 years since November 16, 2023+105.0%+27.0% a yearPrice +88.2%+240.0%+50.4% a yearPrice +240.0%
5 years since November 15, 2021+98.6%+14.7% a yearPrice +72.8%+35.4%+6.2% a yearPrice +35.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonZYMEZymeworks

Valuation

JNJZYME
Valuation
Price$282.55$26.45
Market value$681B$1.8B
Enterprise value (EV)$708B$2.1B
P/E42.342.2
P/E, 5-year median21.9–
P/B8.47.1
EV/EBIT39.946.8
Free cash flow yield3.0%–

Results and growth

JNJZYME
Results and growth
Revenue, 12 months$99.3B$266M
Net income, 12 months$16.1B$43M
Free cash flow, 12 months$20.6B-$113M
Earnings per share, 12 months$6.59$0.63
Revenue growth, year on year6.1%38.9%
Revenue growth a year, past+2.7%over 5 years+22.2%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJZYME
Margins and returns on capital
Gross margin67.6%–
Operating margin–16.6%
Net margin16.2%16.3%
ROIC12.4%16.0%
ROE19.7%19.9%

Balance sheet

JNJZYME
Balance sheet
Cash$17.2B$100M
Total debt$44.7B$392M
Net debt / EBITDA1.15.0
Interest cover18.0×–

Dividends and buybacks

JNJZYME
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%2.3%
Shareholder yield2.7%2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or ZYME

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Zymeworks?

By market value, Johnson & Johnson ($681B) is about 372.9 times Zymeworks ($1.8B), at today's prices.

How did JNJ and ZYME stock do over the last 5 years?

Since November 15, 2021, JNJ's price moved +72.8% and ZYME's +35.4%. With dividends: JNJ +98.6% (+14.7% a year), ZYME +35.4% (+6.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or ZYME?

The dividend yield at today's price is 1.87% for Johnson & Johnson and none for Zymeworks. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and ZYME?

At today's price, the P/E is 42.3 for JNJ and 42.2 for ZYME. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Zymeworks?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 16.3% for Zymeworks, and the operating margin – and 16.6%. Revenue was $99.3B and $266M.

Which is the better investment, Johnson & Johnson or Zymeworks?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.